Anatabloc Cream helps moderate rosacea

Written by on November 28, 2013 in clinical trials, New Rosacea Treatments with 3 Comments
anatabloc-cream

We first heard about Anatabloc Cream (Antabine) a year ago when Rock Creek Pharmaceuticals listed a clinical trial to assess the safety and effects of Anatabine in the appearance of rosacea symptoms.

Now the clinical trial results have been written up in an article in Case Reports in Dermatology. The results are modest, but encouraging – “anatabine can improve the appearance of the skin in patients with mild to moderate rosacea”

The extended conclusion reads “In conclusion, results from this open-label case series show that daily application of a topical facial cream containing the minor alkaloid anatabine is safe and well tolerated and can reduce the signs and symptoms of mild to moderate rosacea. Improving the appearance of the skin by reducing persistent erythema, and possibly other signs and symptoms of rosacea, could lead to an overall increase in the quality of life for those dealing with this chronic disease. A larger, double-blind, vehicle-controlled trial of the anatabine facial cream in subjects with mild to moderate rosacea appears to be warranted.”

The full paper is available online here – http://www.karger.com/Article/FullText/357019

What is Anatabine?

According to the wikipedia article Anatabine is “one of the minor alkaloids found in plants in the Solanaceae family, which includes the tobacco plant and tomato that has been shown to affect monoamine oxidase (MAO) activity.”

Anatabine is also one of the ingredients in the smoking alternative dietary supplement, CiGRX, developed by Rock Creek Pharmaceuticals and is also being examined as a treatment for inflammatory diseases as well as alzheimers.

Article Abstract

Effects of a Facial Cream Containing the Minor Alkaloid Anatabine on Improving the Appearance of the Skin in Mild to Moderate Rosacea: An Open-Label Case Series Study

Case Reports in Dermatology Vol. 5, No. 3, 2013

Lanier R.K.,  Cohen A.E., · Weinkle S.H., Rock Creek Pharmaceuticals, Inc., Gloucester, Mass., and Private practice, Bradenton, Fla., USA

Background: Current medical and scientific research indicates that rosacea, a chronic and often debilitating skin condition that primarily affects the central face, may be caused by an overactive or excessive inflammatory immune response. Regardless of etiology, the accompanying redness and inflammation is unsightly and difficult for the patient. Anatabine is an alkaloid from the plant family Solanaceae that has been shown in several preclinical studies to modulate proinflammatory signaling pathways.

Objective: A cream containing anatabine was developed and evaluated in an open-label case series study for safety and effects on the appearance of the skin in 10 patients with mild to moderate rosacea.

Methods: Patients applied the cream to the face twice daily for a period of 30 days. Patients and the study physician completed safety and efficacy assessments at study end.

Results: Results showed that 50% of the patients self-reported improvement in the appearance of their skin, and the physician noted improvement in 70% of the patients. Photographs taken before and after 30 days of cream use provide visual evidence of the improvement in several patients. There were no complications or adverse events reported by any of the patients in the study, indicating that the anatabine cream was safe and very well tolerated.

Conclusion: The results of this open-label case series show that a facial cream containing anatabine can improve the appearance of the skin in patients with mild to moderate rosacea and suggest that a double-blind, vehicle-controlled trial in a larger number of subjects is warranted.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

3 Reader Comments

  1. David Pascoe says:

    Comment via email from Danny.

    “This study it seems used 10 patients, which is not a significant number of patients to study. With only 10, the results could be found by chance. Also, there is no control group so we don’t know if 50% would improve during this period without the cream. This study only recommends a large, double-blind, study, which of course is required.”

  2. europoljuice says:

    Is this basically the same kind of treatment as in Mirvaso? Do you need a prescription to get this? No rebound affect??

    Europoljuice

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.